Article Details
Retrieved on: 2024-11-03 14:14:29
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The brokerage currently has a “neutral” rating on the biotechnology company's stock. The Goldman Sachs Group's price target points to a potential ...
Article found on: www.defenseworld.net
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here